Clinical trials: PIK3CA Mutations

Breast Cancer

Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus Fulvestrant

• Terminated
• Age: 18 years and older
• Phase 3
• Results posted

The purpose of this clinical trial is to study of the molecular features of postmenopausal women with hormone receptor-positive (HR+) HER2-negative advanced breast cancer on first-line treatment with ribociclib and letrozole and…

Trial name

BioItaLEE (NCT03439046)

Testing

Ribociclib, Letrozole, Alpelisib

Where

41 sites in Italy

Volunteers

287 people

Sponsor

Novartis Pharmaceuticals